The Case For UnitedHealth Stock Is Margin, Not Growth

The Case For UnitedHealth Stock Is Margin, Not Growth

UnitedHealth's revenue held up; the operating margin on it did not, and closing that gap is the whole upside case.

UnitedHealth (UNH) has returned 76% over the past twelve months and still sits about 7% below its high of the past year. After a run like that, the fair question is what is left to pay for. It is not growth: this company used to earn far more on the revenue it already sells, and is visibly working its way back to it.

UnitedHealth's Recovery Has To Come From Margin

Revenue of $449.7 billion over the trailing twelve months is up 9.7%, in line with the company's own three-year pace, so the top line was never the problem. Operating margin over the same window is 4.2%. On a base that large, each point of operating margin is worth roughly $4.5 billion of operating income, which is why the distance back to a three-year peak of 8.8% matters more than anything happening to the top line. Revenue that holds up while the margin on it is being rebuilt is the sort of quality the Trefis High Quality Portfolio looks for in a holding.

Operating Earnings Up 55% On Flat Revenue

The repair has already started. In the second quarter of 2026, revenue of $112 billion was essentially unchanged from a year earlier while operating earnings of $8 billion grew 55%. None of that came from selling more. On that $112 billion of revenue, $8 billion is an operating margin near 7% for the quarter, well above the 4.2% trailing-twelve-month figure. Management calls its own benefit design, care management, and network curation a primary reason for Medicare medical cost trend running below the roughly 10% it had planned for, and now expects Medicare margins to finish 2026 above 3%.

That margin comes with a shrinking book: full-year Medicare Advantage enrollment is set to fall by about 1.1 million. The same discipline shows up at Optum Health in the clinic rather than the spreadsheet: support for patients through care transitions has cut hospitalizations by about 10% in the regions where it has been running, and AI-based ambient listening is now available to 70% of its employed providers.

The Bigger Risk Is Commercial, Not Medicare

The biggest doubt is not Medicare; it is the commercial book. Medical cost trend there is running modestly above 11% and moving the wrong way, and the company has pushed full recovery of commercial margins out past 2027. Some of that sits outside its control, since an independent resolution process it does not run now totals at least 100 basis points of total cost. The test is whether the guide keeps climbing while commercial is still a drag, and so far it has: the full-year 2026 adjusted earnings guide moved from above $18.25 a share in April to a range of $19.50 to $20 in July, and the market has already paid for part of that recovery.

This stock re-rates in bursts, with six separate gains of more than 30% in under two months since 2010, which makes the price a noisy read on the repair and the guide the steadier one. That is exactly what a screen of companies whose guidance keeps rising is for.

A Margin Repair Is Still One Company's Repair

The gap is real, and the company has already closed part of it, but the timetable belongs to one management team inside one regulatory system. A rules-based group of quality businesses, such as the Trefis High Quality Portfolio, spreads that timing risk in a way a single holding cannot. That portfolio has a track record of outpacing the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000.